BERGAMOT

  • What's involved: A Phase III, Randomised, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance treatment for Patients with Moderately to Severely Active Crohn's Disease.
  • Take part: Suspended
  • Principal Investigator: Dr Sunil Samuel
Research Theme | Gastrointestinal & Liver

What's involved

A Phase III, Randomised, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance treatment for Patients with Moderately to Severely Active Crohn's Disease.

Principal Investigator

Dr Sunil Samuel

Take part

Suspended
Back to all trials

Contact Us

NIHR Biomedical Research Centre: Nottingham
Research & Innovation
D Floor (via South Block)
Nottingham University Hospitals NHS Trust
Queen’s Medical Centre
Derby Road
Nottingham
NG7 2UH

Telephone: 0115 924 9924

Director: Professor Ian Hall

Hosted by

Nottingham University Hospitals Logo

Nottingham University Hospitals Logo

We are a partnership between Nottingham University Hospitals NHS Trust and the University of Nottingham, supported by NHS and academic partners in Nottingham and across the East Midlands.

Website by Volute